Information Provided By: 
Fly News Breaks for October 23, 2015
ABBV
Oct 23, 2015 | 07:41 EDT
UBS said the selloff in AbbVie caused by the FDA warning on its Viekira Pak appears to be overdone. The firm believes investors underappreciate the company's improving pipeline and the operating leverage in the business that will drive its earnings power. UBS reiterated its Buy rating and lowered its price target to $78 from $81 on AbbVie shares.
News For ABBV From the Last 2 Days
There are no results for your query ABBV
